Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role

CDT Equity Inc.

David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.
Andrew Regan appointed CEO effective April 15, 2025; continues as director and waives compensation except expense reimbursement.
Faith Charles resigned from board effective April 16, 2025 for personal reasons; board reduced from seven to five members.
Tapolczay to focus on out-licensing tapinarof patents; Regan highlights AI collaboration with Sarborg and 20-year patent strategy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Regan

Chief Executive Officer

CDT · CDT Equity Inc.

Effective: 2025-04-15
Filed: April 16, 2025, 7:59 PM ET

On April 15, 2025, the Company appointed Andrew Regan as Chief Executive Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Regan was appointed as Chief Executive Officer at CDT Equity Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On April 15, 2025, the Company appointed Andrew Regan as Chief Executive Officer, effective immediately.

View on SEC.gov

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.